[en] Knee osteoarthritis is a highly prevalent whole-joint disease that is associated with substantial morbidity. If step changes are to be made in the management of knee osteoarthritis, novel patient stratification approaches are needed to identify the most effective treatment for individual patients. Numerous methods for stratifying patients with knee osteoarthritis can be employed; clinical presentation, including co-morbidity and pain phenotype, can influence treatment decisions, and there is a rich history of imaging biomarker use, both from conventional radiographs and, since its development, via MRI, in identifying patients at risk of disease progression, and the latter facilitates the detection of synovitis. The development of novel biochemical biomarkers and the rapid growth of '-omics' technologies provide fresh opportunities to deploy these advances in the stratification of patients with knee osteoarthritis. The health economic landscape in this area is developing, and scoping work has highlighted the need for further studies.
Disciplines :
Public health, health care sciences & services Laboratory medicine & medical technology
Author, co-author :
Fuggle, Nicholas R ; MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK
Chapurlat, Roland; INSERM UMR 1033, Université Claude Bernard-Lyon 1, Hôpital Edouard-Herriot, Lyon, France
Laslop, Andrea ; Scientific Office, Federal Office for Safety in Health Care, Vienna, Austria
Al-Daghri, Nasser ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé ; Biomarkers of Chronic Disease Chair, Biochemistry Department, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia
Alokail, Majed; Protein Research Chair, Biochemistry Department, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia
Thiyagarajan, Jotheeswaran Amuthavalli; Ageing and Health Unit, World Health Organization, Geneva, Switzerland
Balkowiec-Iskra, Ewa ; Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
Berenbaum, Francis ; Sorbonne University, INSERM, AP-HP Saint-Antoine Hospital, Paris, France
Bemden, Angie Botto-van; Musculoskeletal Research International, Key Biscayne, FL, USA
Borg, John-Joseph; Malta Medicines Authority, San Ġwann, Malta
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Burlet, Nansa ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Cavalier, Etienne ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale
Rosa, Mario M ; Laboratory of Clinical and Therapeutical Pharmacology, University of Lisbon, Lisbon, Portugal
Conaghan, Philip G ; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
Cooper, Cyrus ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé ; MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK ; NIHR Southampton Biomedical Research Centre, University of Southampton, Southampton, UK ; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
Dennison, Elaine M; MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK
Englund, Martin ; Clinical Epidemiology Unit, Orthopedics, Faculty of Medicine, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Im, Gun-Il; Department of Orthopedics, Dongguk University Ilsan Hospital, Goyang Gyeonggi-Do, Republic of Korea
Haugen, Ida K; Center for Treatment of Rheumatic and Musculoskeletal Diseases, Diakonhjemmet Hospital, Oslo, Norway
Hiligsmann, Mickaël ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé ; Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, the Netherlands
Kurth, Andreas; Johann Wolfgang Goethe University, Frankfurt, Germany
Lane, Nancy ; Department of Medicine, University of California Davis, Sacramento, CA, USA
Lories, Rik; Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven and Division of Rheumatology, UZ Leuven, Leuven, Belgium
Marlovits, Stefan; Centre for Cartilage Regeneration, Orthobiologics and Joint Preservation, Vienna, Austria
Matijevic, Radmila; University of Novi Sad, Faculty of Medicine, Clinic for Orthopedic Surgery and Traumatology, Clinical Center of Vojvodina, Novi Sad, Serbia
Mobasheri, Ali ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé ; Research Unit of Health Sciences and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland ; Department of Regenerative Medicine, State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania ; Department of Joint Surgery, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
Ormarsdóttir, Sif; Medicine Assessment and Licencing, Icelandic Medicines Agency, Reykjavik, Iceland
Yerro, Maria C Prieto; Agencia Española de Medicamentos Y Productos Sanitarios, Madrid, Spain
Radermecker, Régis ; Université de Liège - ULiège > Département des sciences cliniques > Pharmacologie clinique
Rannou, François ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé ; Service de Rééducation et de Réadaptation de l'Appareil Locomoteur et des Pathologies du Rachis, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France
Sepodes, Bruno; Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal ; Laboratory of Systems Integration Pharmacology, Clinical and Regulatory Science, Research Institute for Medicines of the University of Lisbon, Lisbon, Portugal
Silverman, Stuart; Cedars-Sinai Medical Center, Los Angeles, CA, USA
Torre, Carla; Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal ; Laboratory of Systems Integration Pharmacology, Clinical and Regulatory Science, Research Institute for Medicines of the University of Lisbon, Lisbon, Portugal
Veronese, Nicola ; Saint Camillus International University of Health Sciences, Rome, Italy
Rizzoli, René ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé ; Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique ; Protein Research Chair, Biochemistry Department, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia
Harvey, Nicholas C ; MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK. nch@mrc.soton.ac.uk ; NIHR Southampton Biomedical Research Centre, University of Southampton, Southampton, UK. nch@mrc.soton.ac.uk
R.C., N.A-D., M.A., J.A.T., J.-J.B., N.B., E.C., M.M.R, C.C., G.I.I., A.K., N.L., S.M., R.M., S.O., M.C.P.Y., R.P.R., F.R., B.S., S.S., C.T., A.L. and E.B.I. declare no competing interests. N.R.F. has received speaker fees and honoraria from UCB and Viatris and travel bursaries from Pfizer and Eli Lilly. F.B. reports personal fees from 4\u2009P Pharma, 4Moving Biotech, Grunenthal, GSK, Heel, Nordic Bioscience, Novartis, Servier, TRB Chemedica and Viatris. O.B. has received consulting or lecture fees from Amgen, Aptissen, Biophytis, IBSA, Mylan, Novartis, Nutricia, Orifarm, Sanofi, UCB and Viatris. P.G.C. has performed consultancies or speakers bureaus for Eli Lilly, Eupraxia, Formation Bio, Galapagos, Genascence, GSK, Grunenthal, Janssen, Kolon TissueGene, Levicept, Medipost, Moebius, Novartis, Pacira, Sandoz and Stryker & Takeda. E.M.D. reports honoraria from UCB, Viatris and Pfizer. M.E. reports consultancy for Gr\u00FCnenthal Sweden AB and Key2Compliance. I.K.H. reports personal fees from Novartis, AbbVie, Gr\u00FCnenthal and GSK during the past 36 months. M.H. reports in the past 36 months research grants (paid to institution) from Radius Heath and Angelini Pharma, as well as lecture or consulting fees (all paid to institution) from Grunenthal, Pfizer, Mylan Pharmaceuticals and IBSA. Leuven R&D and the valorization division of KU Leuven, and has received speaker fees and honoraria from AbbVie, Amgen, Galapagos, Biosplice (formerly Samumed), Biocon (formerly Viatris), Eli-Lilly, Novartis and UCB on behalf of R.L. A.M. has received speaker fees and honoraria from HALEON, Gr\u00FCnenthal, Kolon TissueGene, Kolon Life Science Cluster, Aptissen SA, California Institute for Regenerative Medicine (CIRM), Sanofi, Sanofi Consumer Healthcare, GSK, Novartis, Pfizer, Viatris, Contura, Enlivex, Orion Corporation, Pluri, Pacira Biosciences, Laboratoires Expanscience and Synartro Ampio Pharmaceuticals. N.V. reports personal fees from IBSA, Mylan, Viatris, Sanofi, Nestl\u00E8 and Fidia outside of the submitted work. R.R. has received fees for advisory board or lectures from Abiogen, Effryx and Theramex. J-Y.R. reports consulting fees or paid advisory boards for IBSA-Genevrier, Mylan, Radius Health, Pierre Fabre, Faes Pharma, Rejuvenate Biomed, Samumed, Teva, Theramex, Pfizer and Mithra Pharmaceuticals, lecture fees when speaking at the invitation of sponsor for IBSA-Genevrier, Mylan, Cniel, Dairy Research Council, Nutricia, Danone and Agnovos, and grant support from IBSA-Genevrier, Mylan, Cniel, Radius Health and TRB. N.C.H reports personal fees, consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, UCB, Kyowa Kirin, Servier, Shire, Consilient Healthcare, Theramex and Internis Pharma.The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group that produced this Perspective article was funded by the ESCEO. The ESCEO receives unrestricted educational grants to support its educational and scientific activities from non-governmental organizations, not-for-profit organizations, non-commercial or corporate partners. The choice of topics, participants, content and agenda of the working groups, as well as the writing, editing, submission and reviewing of the manuscript, are the sole responsibility of the ESCEO, without any influence from third parties. J.-Y. R. was supported by the Distinguished Scientist Fellowship Program of the King Saud University, Riyadh, Kingdom of Saudi Arabia. E.B.-I. would like to acknowledge their affiliation to The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Warsaw, Poland. E. B.-I. and J.-J.B. would like to acknowledge their affiliation with the EMA Committee for Medicinal Products for Human Use, Amsterdam, the Netherlands.\u00A0The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agency with which the authors are affiliated.
A. Cui et al. Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies EClinicalMedicine 29–30 34505846 7704420 10.1016/j.eclinm.2020.100587 100587
L. Murphy et al. Lifetime risk of symptomatic knee osteoarthritis Arthritis Rheum. 59 1207 1213 18759314 4516049 10.1002/art.24021
X. Jin et al. Economic and humanistic burden of osteoarthritis: an updated systematic review of large sample studies Pharmacoeconomics 41 1453 1467 37462839 10.1007/s40273-023-01296-1
H. Long et al. Prevalence trends of site-specific osteoarthritis from 1990 to 2019: findings from the global burden of disease study 2019 Arthritis Rheumatol. 74 1172 1183 35233975 9543105 10.1002/art.42089
D. Prieto-Alhambra et al. Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: influences of age, gender and osteoarthritis affecting other joints Ann. Rheum. Dis. 73 1659 1664 23744977 10.1136/annrheumdis-2013-203355
R. Altman et al. Development of criteria for the classification and reporting of osteoarthritis. classification of osteoarthritis of the knee. diagnostic and therapeutic criteria committee of the American Rheumatism Association Arthritis Rheum. 29 1039 1049 3741515 10.1002/art.1780290816 1:STN:280:DyaL283psF2msQ%3D%3D
W. Zhang et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis Ann. Rheum. Dis. 69 483 489 19762361 10.1136/ard.2009.113100 1:STN:280:DC%2BC3c7nsFGlsg%3D%3D
Q. Wang et al. Evaluation of the diagnostic performance of American College of Rheumatology, EULAR, and national institute for health and clinical excellence criteria against clinically relevant knee osteoarthritis: data from the CHECK cohort Arthritis Care Res. 76 511 516 10.1002/acr.25270
Q. Wang et al. Diagnosis for early stage knee osteoarthritis: probability stratification, internal and external validation; data from the CHECK and OAI cohorts Semin. Arthritis Rheum. 55 35468448 10.1016/j.semarthrit.2022.152007 152007
A. Mahmoudian L.S. Lohmander A. Mobasheri M. Englund F.P. Luyten Early-stage symptomatic osteoarthritis of the knee — time for action Nat. Rev. Rheumatol. 17 621 632 34465902 10.1038/s41584-021-00673-4
N.K. Arden et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines Nat. Rev. Rheumatol. 17 59 66 33116279 10.1038/s41584-020-00523-9 1:CAS:528:DC%2BB3cXitlWgt7zP
R.R. Bannuru et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis Osteoarthritis Cartilage 27 1578 1589 31278997 10.1016/j.joca.2019.06.011 1:STN:280:DC%2BB3MzkslSqsw%3D%3D
O. Bruyère et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO) Semin. Arthritis Rheum. 49 337 350 31126594 10.1016/j.semarthrit.2019.04.008
N. Veronese et al. Multimodal multidisciplinary management of patients with moderate to severe pain in knee osteoarthritis: a need to meet patient expectations Drugs 82 1347 1355 36112341 9512723 10.1007/s40265-022-01773-5
J.S. Kim et al. FDA/arthritis foundation osteoarthritis drug development workshop recap: assessment of long-term benefit Semin. Arthritis Rheum. 56 35870222 9452453 10.1016/j.semarthrit.2022.152070 152070
M. Englund A. Turkiewicz Pain in clinical trials for knee osteoarthritis: estimation of regression to the mean Lancet Rheumatol. 5 e309 e311 38251596 10.1016/S2665-9913(23)00090-5 1:CAS:528:DC%2BB3sXosFahtbY%3D
F. Berenbaum et al. General safety and tolerability of subcutaneous tanezumab for osteoarthritis: a pooled analysis of three randomized, placebo-controlled trials Arthritis Care Res. 74 918 928 10.1002/acr.24637
M. Hiligsmann et al. Patients’ preferences for osteoarthritis treatment: the value of stated-preference studies Aging Clin. Exp. Res. 31 1 3 30607878 6390947 10.1007/s40520-018-1098-3
The Professional Society for Health Economics and Outcomes Research. Patient-Centered Special Interest Group. https://www.ispor.org/member-groups/special-interest-groups/patient-centered (2025).
I.N. Ackerman et al. Preferences for disease-related education and support among younger people with hip or knee osteoarthritis Arthritis Care Res. 69 499 508 10.1002/acr.22950
S. Bunzli et al. Misconceptions and the acceptance of evidence-based nonsurgical interventions for knee osteoarthritis. a qualitative study Clin. Orthop. Relat. Res. 477 1975 1983 31192807 7000096 10.1097/CORR.0000000000000784
A. Botto-van Bemden A.O. Adebajo C.M. Fitzpatrick Patient and public involvement in rheumatic and musculoskeletal research: an idea whose time has firmly come BMC Rheumatol. 7 12 37254198 10229221 10.1186/s41927-023-00340-z
D.T. Felson Y. Zhang An update on the epidemiology of knee and hip osteoarthritis with a view to prevention Arthritis Rheum. 41 1343 1355 9704632 10.1002/1529-0131(199808)41:8<1343::AID-ART3>3.0.CO;2-9 1:STN:280:DyaK1czmvVegsg%3D%3D
C. Parsons et al. How well do radiographic, clinical and self-reported diagnoses of knee osteoarthritis agree? Findings from the Hertfordshire cohort study Springerplus 4 25932366 4408304 10.1186/s40064-015-0949-z 177
C. Parsons et al. Concordance between clinical and radiographic evaluations of knee osteoarthritis Aging Clin. Exp. Res. 30 17 25 29101670 10.1007/s40520-017-0847-z
T. Neogi et al. Association between radiographic features of knee osteoarthritis and pain: results from two cohort studies BMJ 339 b2844 19700505 2730438 10.1136/bmj.b2844
S.L. Smith D.A. Walsh Osteoarthritis pain phenotypes: how best to cut the cake? Osteoarthritis Cartilage 32 124 127 38006965 10.1016/j.joca.2023.11.008
D. Zhang L.A. Deveza B.Y. Tan B. Dear D.J. Hunter Antidepressants to manage osteoarthritic pain: the value of pain phenotyping Drugs Aging 42 183 193 39976814 11880052 10.1007/s40266-025-01182-9
A.J. Knights S.J. Redding T. Maerz Inflammation in osteoarthritis: the latest progress and ongoing challenges Curr. Opin. Rheumatol. 35 128 134 36695054 10.1097/BOR.0000000000000923
F. Pegreffi et al. Prevalence of sarcopenia in knee osteoarthritis: a systematic review and meta-analysis J. Clin. Med. 12 1532 36836065 9963114 10.3390/jcm12041532
K. Moradi et al. Erosive hand osteoarthritis and sarcopenia: data from Osteoarthritis Initiative cohort Ann. Rheum. Dis. 83 799 806 38242637 10.1136/ard-2023-224997
Z. Jin R. Wang L. Jin L. Wan Y. Li Causal relationship between sarcopenia with osteoarthritis and the mediating role of obesity: a univariate, multivariate, two-step mendelian randomization study BMC Geriatr. 24 38811889 11138082 10.1186/s12877-024-05098-8 1:CAS:528:DC%2BB2cXht1WhsrjI 469
M. Pineda-Moncusí et al. Classification of patients with osteoarthritis through clusters of comorbidities using 633330 individuals from Spain Rheumatology 62 3592 3600 36688706 10629784 10.1093/rheumatology/kead038
T. Ramazanian S. Fu S. Sohn M.J. Taunton H.M. Kremers Prediction models for knee osteoarthritis: review of current models and future directions Arch. Bone Jt Surg. 11 1 11 36793660 9903309
F. Foppiano B. Schaub Childhood asthma phenotypes and endotypes: a glance into the mosaic Mol. Cell Pediatr. 10 9 37646843 10469115 10.1186/s40348-023-00159-1
L.A. Deveza A.E. Nelson R.F. Loeser Phenotypes of osteoarthritis: current state and future implications Clin. Exp. Rheumatol. 37 64 72 31621574 6936212
A. Mobasheri R. Loeser Clinical phenotypes, molecular endotypes and theratypes in OA therapeutic development Nat. Rev. Rheumatol. 20 525 526 38760581 10.1038/s41584-024-01126-4
W.E. Van Spil O. Kubassova M. Boesen A.C. Bay-Jensen A. Mobasheri Osteoarthritis phenotypes and novel therapeutic targets Biochem. Pharmacol. 165 41 48 30831073 10.1016/j.bcp.2019.02.037
G.E. Ehrlich Osteoarthritis beginning with inflammation. Definitions and correlations JAMA 232 157 159 1172989 10.1001/jama.1975.03250020031020 1:STN:280:DyaE2M7hs12kug%3D%3D
F. Berenbaum Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!) Osteoarthritis Cartilage 21 16 21 23194896 10.1016/j.joca.2012.11.012 1:STN:280:DC%2BC3s7nsFakuw%3D%3D
A. Mobasheri et al. Molecular taxonomy of osteoarthritis for patient stratification, disease management and drug development: biochemical markers associated with emerging clinical phenotypes and molecular endotypes Curr. Opin. Rheumatol. 31 80 89 30461544 10.1097/BOR.0000000000000567
W.H. Robinson et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis Nat. Rev. Rheumatol. 12 580 592 27539668 5500215 10.1038/nrrheum.2016.136 1:CAS:528:DC%2BC28XhsVSlsrvI
E.M. van Helvoort et al. Cohort profile: the applied public-private research enabling osteoarthritis clinical headway (IMI-APPROACH) study: a 2-year, European, cohort study to describe, validate and predict phenotypes of osteoarthritis using clinical, imaging and biochemical markers BMJ Open 10 32723735 7389775 10.1136/bmjopen-2019-035101 e035101
M. Schieker et al. Effects of interleukin-1β inhibition on incident hip and knee replacement: exploratory analyses from a randomized, double-blind, placebo-controlled trial Ann. Intern. Med. 173 509 515 32744862 8503784 10.7326/M20-0527
A. Mobasheri et al. Recent advances in understanding the phenotypes of osteoarthritis F1000Res. 8 F1000 31885861 6913225 10.12688/f1000research.20575.1
J.E. Collins T. Neogi E. Losina Trajectories of structural disease progression in knee osteoarthritis Arthritis Care Res. 73 1354 1362 10.1002/acr.24340
F.W. Roemer et al. Can structural joint damage measured with MR imaging be used to predict knee replacement in the following year? Radiology 274 810 820 25279436 10.1148/radiol.14140991
M.A. Karsdal et al. OA phenotypes, rather than disease stage, drive structural progression — identification of structural progressors from 2 phase III randomized clinical studies with symptomatic knee OA Osteoarthritis Cartilage 23 550 558 25576879 10.1016/j.joca.2014.12.024 1:STN:280:DC%2BC2MvltlOiuw%3D%3D
J.E. Collins et al. Semiquantitative imaging biomarkers of knee osteoarthritis progression: data from the foundation for the national institutes of health osteoarthritis biomarkers consortium Arthritis Rheumatol. 68 2422 2431 27111771 5599158 10.1002/art.39731 1:CAS:528:DC%2BC28XhsFKkt7fI
K. Bacon M.P. LaValley S.R. Jafarzadeh D. Felson Does cartilage loss cause pain in osteoarthritis and if so, how much? Ann. Rheum. Dis. 79 1105 1110 32381567 10.1136/annrheumdis-2020-217363 1:CAS:528:DC%2BB3cXhvF2htb%2FM
X. Ayral E.H. Pickering T.G. Woodworth N. Mackillop M. Dougados Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis — results of a 1 year longitudinal arthroscopic study in 422 patients Osteoarthritis Cartilage 13 361 367 15882559 10.1016/j.joca.2005.01.005 1:STN:280:DC%2BD2M3ksFanug%3D%3D
F.W. Roemer et al. Presence of MRI-detected joint effusion and synovitis increases the risk of cartilage loss in knees without osteoarthritis at 30-month follow-up: the MOST study Ann. Rheum. Dis. 70 1804 1809 21791448 10.1136/ard.2011.150243
S. Ramezanpour et al. Impact of sustained synovitis on knee joint structural degeneration: 4-Year MRI data from the osteoarthritis initiative J. Magn. Reson. Imaging 57 153 164 35561016 10.1002/jmri.28223
P.G. Conaghan et al. Clinical and ultrasonographic predictors of joint replacement for knee osteoarthritis: results from a large, 3-year, prospective EULAR study Ann. Rheum. Dis. 69 644 647 19433410 10.1136/ard.2008.099564 1:STN:280:DC%2BC3c7ovFentA%3D%3D
D.T. Felson et al. Bone marrow edema and its relation to progression of knee osteoarthritis Ann. Intern. Med. 139 330 336 12965941 10.7326/0003-4819-139-5_Part_1-200309020-00008
E. Yusuf M.C. Kortekaas I. Watt T.W. Huizinga M. Kloppenburg Do knee abnormalities visualised on MRI explain knee pain in knee osteoarthritis? A systematic review Ann. Rheum. Dis. 70 60 67 20829200 10.1136/ard.2010.131904
F.W. Roemer J.E. Collins T. Neogi M.D. Crema A. Guermazi Association of knee OA structural phenotypes to risk for progression: a secondary analysis from the foundation for national institutes of health osteoarthritis biomarkers study (FNIH) Osteoarthritis Cartilage 28 1220 1228 32433936 10622165 10.1016/j.joca.2020.05.008 1:STN:280:DC%2BB38vpsFWqsQ%3D%3D
F.W. Roemer et al. Change in MRI-detected subchondral bone marrow lesions is associated with cartilage loss: the MOST Study. A longitudinal multicentre study of knee osteoarthritis Ann. Rheum. Dis. 68 1461 1465 18829615 10.1136/ard.2008.096834 1:STN:280:DC%2BD1MrltVSjsw%3D%3D
D.J. Hunter et al. Increase in bone marrow lesions associated with cartilage loss: a longitudinal magnetic resonance imaging study of knee osteoarthritis Arthritis Rheum. 54 1529 1535 16646037 10.1002/art.21789
C. McCague et al. Introduction to radiomics for a clinical audience Clin. Radiol. 78 83 98 36639175 10.1016/j.crad.2022.08.149 1:STN:280:DC%2BB28novVGquw%3D%3D
S. Li et al. Integrating radiomics and neural networks for knee osteoarthritis incidence prediction Arthritis Rheumatol. 76 1377 1386 38751101 10.1002/art.42915 1:CAS:528:DC%2BB2cXhsFaqtb7L
S. Gao et al. Cartilage T2 mapping-based radiomics in knee osteoarthritis research: Status, progress and future outlook Eur. J. Radiol. 181 39522425 10.1016/j.ejrad.2024.111826 111826
M.A. Bowes et al. Machine-learning, MRI bone shape and important clinical outcomes in osteoarthritis: data from the Osteoarthritis Initiative Ann. Rheum. Dis. 80 502 508 33188042 10.1136/annrheumdis-2020-217160
J.C. Rousseau R. Chapurlat P. Garnero Soluble biological markers in osteoarthritis Ther. Adv. Musculoskelet. Dis. 13 1759720x211040300 34616494 8488516 10.1177/1759720X211040300 1:CAS:528:DC%2BB38Xhs1SrsA%3D%3D
C. Kjelgaard-Petersen et al. Establishment of a human synovium and cartilage co-culture Osteoarthritis Cartilage 25 S276 S277 10.1016/j.joca.2017.02.468
V.B. Kraus et al. Predictive validity of biochemical biomarkers in knee osteoarthritis: data from the FNIH OA biomarkers consortium Ann. Rheum. Dis. 76 186 195 27296323 10.1136/annrheumdis-2016-209252 1:CAS:528:DC%2BC1cXhsFaiurY%3D
P. Garnero E. Sornay-Rendu R. Chapurlat The cartilage degradation marker, urinary CTX-II, is associated with the risk of incident total joint replacement in postmenopausal women. A 18 year evaluation of the OFELY prospective cohort Osteoarthritis Cartilage 28 468 474 31982562 10.1016/j.joca.2019.12.012 1:STN:280:DC%2BB38%2FksFyruw%3D%3D
P. Garnero E. Gineyts J.C. Rousseau E. Sornay-Rendu R.D. Chapurlat Plasma cartilage acidic protein 1 measured by ELISA is associated with the progression to total joint replacement in postmenopausal women J. Rheumatol. 51 176 180 37914215 10.3899/jrheum.2023-0684 1:CAS:528:DC%2BB2cXmslaqu74%3D
J.C. Rousseau E. Sornay-Rendu C. Bertholon P. Garnero R. Chapurlat Serum periostin is associated with prevalent knee osteoarthritis and disease incidence/progression in women: the OFELY study Osteoarthritis Cartilage 23 1736 1742 26072384 10.1016/j.joca.2015.05.015 1:STN:280:DC%2BC2Mbjt1aqtA%3D%3D
J.C. Rousseau et al. Association of circulating microRNAs with prevalent and incident knee osteoarthritis in women: the OFELY study Arthritis Res. Ther. 22 2 31898522 6941326 10.1186/s13075-019-2086-5 1:CAS:528:DC%2BB3cXmtVyhsg%3D%3D
S.P. Yu et al. Association of biochemical markers with bone marrow lesion changes on imaging-data from the foundation for the national institutes of health osteoarthritis biomarkers consortium Arthritis Res. Ther. 26 30 38238803 10795356 10.1186/s13075-023-03253-x 1:CAS:528:DC%2BB2cXitFOhs7g%3D
V.B. Kraus J. Catterall E. Soderblom M.A. Moseley S. Suchindran Development of a serum biomarker panel highly predictive of a knee osteoarthritis diagnosis Osteoarthritis Cartilage 24 S72 10.1016/j.joca.2016.01.156
K. Zhou et al. A “best-in-class” systemic biomarker predictor of clinically relevant knee osteoarthritis structural and pain progression Sci. Adv. 9 36696492 9876540 10.1126/sciadv.abq5095 1:CAS:528:DC%2BB3sXjsFWmsLg%3D eabq5095
V.B. Kraus et al. An osteoarthritis pathophysiological continuum revealed by molecular biomarkers Sci. Adv. 10 38669329 11051665 10.1126/sciadv.adj6814 1:CAS:528:DC%2BB2cXpvF2ksLs%3D eadj6814
Council Conclusions on Personalised Medicine for Patients. European Commission. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A52015XG1217%2801%29&qid=1753365910739 (2015).
R.G. Harrison The outgrowth of the nerve fiber as a mode of protoplasmic movement J. Exp. Zool. 9 787 846 10.1002/jez.1400090405
D. Lee A. Erickson A.T. Dudley S. Ryu A microfluidic platform for stimulating chondrocytes with dynamic compression J. Vis. Exp. 10.3791/59676 31885369
H. Liu et al. Cartilage-on-a-chip with magneto-mechanical transformation for osteoarthritis recruitment Bioact. Mater. 33 61 68 38024232
J. Rosser et al. Microfluidic nutrient gradient-based three-dimensional chondrocyte culture-on-a-chip as an in vitro equine arthritis model Mater. Today Bio. 4 32159153 7061638 10.1016/j.mtbio.2019.100023 1:STN:280:DC%2BB383itFCqtw%3D%3D 100023
M. Pasztorek et al. Exploring osteoarthritis dynamics: patient-specific cartilage samples in an organ-on-a-chip model Cartilage 10.1177/19476035241277654 39235338 11569566
C. McCabe K. Claxton A.J. Culyer The NICE cost-effectiveness threshold: what it is and what that means Pharmacoeconomics 26 733 744 18767894 10.2165/00019053-200826090-00004
E. Losina et al. Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume Arch. Intern. Med. 169 1113 1121 19546411 2731300 10.1001/archinternmed.2009.136 discussion 21–2
K. Mari P. Dégieux F. Mistretta F. Guillemin P. Richette Cost utility modeling of early vs late total knee replacement in osteoarthritis patients Osteoarthritis Cartilage 24 2069 2076 27492465 10.1016/j.joca.2016.07.013 1:STN:280:DC%2BC2s3nvFahtg%3D%3D
D.R. Mazzei et al. Are education, exercise and diet interventions a cost-effective treatment to manage hip and knee osteoarthritis? A systematic review Osteoarthritis Cartilage 29 456 470 33197558 10.1016/j.joca.2020.10.002 1:STN:280:DC%2BB3s3lsFagtg%3D%3D
J. Shi et al. Cost effectiveness of pharmacological management for osteoarthritis: a systematic review Appl. Health Econ. Health Policy 20 351 370 35138600 9021110 10.1007/s40258-022-00717-0
I.A. Szilagyi et al. Plasma proteomics identifies CRTAC1 as a biomarker for osteoarthritis severity and progression Rheumatology 62 1286 1295 35924962 10.1093/rheumatology/keac415
S.S. Groen et al. Investigating protease-mediated peptides of inflammation and tissue remodeling as biomarkers associated with flares in psoriatic arthritis Arthritis Res. Ther. 26 107 38802975 11129460 10.1186/s13075-024-03332-7 1:CAS:528:DC%2BB2cXht1Cqu7rM
R.M. Stecher Heberden’s nodes: the clinical characteristic of osteo-arthritis of the fingers Ann. Rheum. Dis. 7 1 8 18910652 1011609 10.1136/ard.7.1.1
H. Long R. Cao H. Yin F. Yu A. Guo Associations between obesity, diabetes mellitus, and cardiovascular disease with progression states of knee osteoarthritis (KOA) Aging Clin. Exp. Res. 35 333 340 36525243 10.1007/s40520-022-02312-8
G. Herrero-Beaumont et al. Systemic osteoarthritis: the difficulty of categorically naming a continuous condition Aging Clin. Exp. Res. 36 45 38376694 10879223 10.1007/s40520-024-02714-w
